Immunovant Sets Q4 2026 Earnings Release for May 20
IMVT forecasts a Q4 EPS of -$0.63 and $0M revenue, with recent upward revisions to earnings estimates. Immunovant (IMVT) will report Q4 2026 earnings on May 20 before the market opens. Analysts expect a loss of $0.63 per share, improving 1.6% year-over-year, and revenue of